Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TRIAMCINOLONE IMPURITY C CRS (10 MG)

TRIAMCINOLONE IMPURITY C CRS (10 MG)

NA

DISCOVER
ERYSIPELAS ELISA COATING ANTIGEN BRP (0.4 MG)

ERYSIPELAS ELISA COATING ANTIGEN BRP (0.4 MG)

NA

DISCOVER
EQUILIN CRS (20 MG)

EQUILIN CRS (20 MG)

474-86-2

DISCOVER
17 ALPHA-DIHYDROEQUILIN CRS (10 MG)

17 ALPHA-DIHYDROEQUILIN CRS (10 MG)

NA

DISCOVER
ALPROSTADIL CRS (25 MG)

ALPROSTADIL CRS (25 MG)

745-65-3

DISCOVER
Acamprosate calcium - reference spectrum, Qty : n/a

Acamprosate calcium - reference spectrum, Qty : n/a

NA

DISCOVER
ACECLOFENAC - REFERENCE SPECTRUM (N/A)

ACECLOFENAC - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
HEPTAMINOL IMPURITY A CRS (25MG)

HEPTAMINOL IMPURITY A CRS (25MG)

NA

DISCOVER
PARAFFIN (LIQUID) - REFERENCESPECTRUM (N/A)

PARAFFIN (LIQUID) - REFERENCESPECTRUM (N/A)

NA

DISCOVER
Pipemidic acid trihydrate - reference spectrum, Qty : n/a

Pipemidic acid trihydrate - reference spectrum, Qty : n/a

NA

DISCOVER
ZUCLOPENTHIXOL DECANOATE- REFERENCE SPECTRUM (NIA)

ZUCLOPENTHIXOL DECANOATE- REFERENCE SPECTRUM (NIA)

NA

DISCOVER
HEPTAMINOL HYDROCHLORIDE CRS (120 MG)

HEPTAMINOL HYDROCHLORIDE CRS (120 MG)

543-15-7

DISCOVER